Beikang Medical

Suzhou, China Founded: 2010 • Age: 16 yrs Listed
NGS-based diagnostic solutions for neonatal screening are developed.

About Beikang Medical

Beikang Medical is a publicly listed company based in Suzhou (China) founded in 2010. NGS-based diagnostic solutions for neonatal screening are developed. Beikang Medical has raised $36.52 million across 2 funding rounds from investors including Broad Vision Funds. The company has 497 employees. Beikang Medical has completed 1 acquisition, including BMX Holdco. Its focus areas include Life Sciences, Women Health, In Vitro Diagnostic Tests and Diversified. Its competitors include Novogene Corporation and BGI; 1 of its 2 listed competitors has raised funding.

Company details

Beikang Medical was founded in 2010 in Suzhou, China, within the genetic diagnostics sector. NGS-based solutions for neonatal and prenatal applications are developed and offered. Tests including pre-pregnancy, pre-implantation, non-invasive prenatal, and earlyneonatal genetic screening are provided under the Basecare brand. Operations are supported by Daan Gene Corp. of Sun Yat-Sen University, with the domain basecare.cn utilized.

  • Headquarters Suzhou, China
  • Employees 497
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website basecare.cn
  • Social X Facebook
  • Legal Name Suzhou Basecare Medical Corp. Ltd. Class H
Key Metrics
  • Annual Revenue
    $32.5 M (USD)
    -21.99
    as on Dec 31, 2025
  • Net Profit
    -$31.13 M (USD)
    5.7
    as on Dec 31, 2025
  • EBITDA
    -$23.2 M (USD)
    30.9
    as on Dec 31, 2025
  • Total Equity Funding
    $36.52M (USD)

    in 2 rounds

  • Latest Funding Round
    $21.13M (USD), Series C

    May 2020

  • Investors
  • Employee Count
    497
  • Investments & Acquisitions

Funding Insights of Beikang Medical

Beikang Medical has successfully raised a total of $36.52M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $21.13 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $36.52M
  • Total Rounds 2
  • Last Round Series C β€” $21.13M
  • First Round $15.38M

    (Sep 2017)

  • Investors Count 1

All 2 funding rounds of Beikang Medical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2020$21.13MSeries C–Broad Vision Funds
–
Sep 2017$15.38MSeries B––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Beikang Medical

Beikang Medical has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Broad Vision Funds.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Consumer technology, healthcare, and sectors are targeted for venture investments.
broadvisionfunds.comBeijing, China
Premium access

Investor details for Beikang Medical

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

IPO & Listings of Beikang Medical

Beikang Medical is a publicly listed company on the HKEX with ticker symbol 2170 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date08 Feb 2021
  • Listed onHKG: 2170
  • Listed entitySuzhou Basecare Medical Corp. Ltd. Class H
  • Exchange sectorHealth technology
  • ISINCNE100004BC1
  • Share price1.30 HKD · 2026-10-14
  • Market capitalisation355,583,789.00 HKD
  • EPS (diluted, trailing year)-0.71 HKD
  • Volume (last session)13,500

Financials of Beikang Medical

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025253.0M HKD-242.3M HKD-180.6M HKD
2024324.3M HKD-257.0M HKD-261.4M HKD
2023229.8M HKD-211.8M HKD-251.9M HKD
2022163.8M HKD-153.2M HKD-249.1M HKD
2021129.3M HKD-173.1M HKD-146.2M HKD
Premium access

Detailed financial statements for Beikang Medical

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Beikang Medical

Beikang Medical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include BMX Holdco.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Multiple industries are operated by the diversified conglomerate.
Singapore2022May 2023β€’β€’β€’β€’
Premium access

Complete acquisition details for Beikang Medical

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Beikang Medical

5 dated milestones of Beikang Medical across 13 years, from founding to its latest funding, stage changes and deals.

  1. Founded Beikang Medical is founded.
  2. Funding First funding round of $15.4M.
  3. Funding Latest funding round, Series C, of $21.1M.
  4. IPO Lists on the stock exchange (IPO).
  5. Acquisition Acquires BMX Holdco.

Competitors of Beikang Medical

Beikang Medical has 2 listed competitors in our database, 1 of them funded. They include Novogene Corporation and BGI.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
novogene.com2011Beijing, China$75M141
Genomic services and solutions with NGS expertise are provided.
bgi.com1999Shenzhen, China25
BGI is engaged in genomics and precision medicine solutions.
Premium access

Detailed competitors of Beikang Medical

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Beikang Medical

The website of Beikang Medical (basecare.cn) receives about 3.2K visits a month.

  • Monthly visits
    3.2K

    ▲ 83.5% vs previous month

Similar websites

Websites whose visitors overlap most with Beikang Medical. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
orbusneich.com
100%
9K#2,415,384View details
tiantu.com.cn
tiantu.com.cn
78%
–
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Beikang Medical

Premium access

Complete news archive for Beikang Medical

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Beikang Medical

Beikang Medical was founded in 2010 and raised its 1st funding round 7 years after it was founded.

Beikang Medical is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.

Beikang Medical is a funded company, having raised a total of $36.52M across 2 funding rounds to date. The company's 1st funding round was a Series B of $15.38M, raised on Sep 2017.

Beikang Medical has 497 employees.

Annual revenue of Beikang Medical is $32.5M as on Dec 31, 2025.

Beikang Medical was founded in 2010 in Suzhou, China, within the genetic diagnostics sector. NGS-based solutions for neonatal and prenatal applications are developed and offered. Tests including pre-pregnancy, pre-implantation, non-invasive prenatal, and earlyneonatal genetic screening are provided under the Basecare brand. Operations are supported by Daan Gene Corp. of Sun Yat-Sen University, with the domain basecare.cn utilized.

Beikang Medical's top competitors include Novogene Corporation and BGI.

Yes, Beikang Medical is publicly traded on HKEX under the ticker symbol 2170.

Beikang Medical has made 1 acquisition, including BMX Holdco.

Beikang Medical has 1 investor. Key investors include Broad Vision Funds.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available